Rufinamidin Dirençli Epilepsi Tedavisindeki Etkinliğinin Araştırılması: Tek Merkez Deneyimi
Izmir Katip Celebi University Faculty of Medicine · 2021
DOI: 10.52818/cjmrtu.2021.1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Izmir Katip Celebi University Faculty of Medicine, 2021. Verfasst von Mehmet Saraçoğlu und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Resistant epilepsy is a neurological condition that affects the quality of life with high morbidity seen in 10% of childhood epilepsy. Treatment options for resistant epilepsy are very limited. Rufinamide is one of the new 3rd generation antiepileptic drugs. In this study, we aimed to investigate the efficacy of rufinamide in treatment of resistant epilepsy. All patients who received rufinamide treatment in our clinic were included in the study. The efficacy of rufinamide was determined by the variability in seizure frequency. According to the results of our study, rufinamide treatment is more effective in reducing the frequency of seizures in patients followed-up with Lennox-Gastatut syndrome, and it is an effective and reliable additional treatment option in resistant epilepsy patients with non-LGS.
Zitieren
APA
Saraçoğlu, M., Bozkurt, Ö., Duman, Ö., & Haspolat, Ş. (2021). Rufinamidin Dirençli Epilepsi Tedavisindeki Etkinliğinin Araştırılması: Tek Merkez Deneyimi. Izmir Katip Celebi University Faculty of Medicine. https://doi.org/10.52818/cjmrtu.2021.1
Vancouver
Saraçoğlu M, Bozkurt Ö, Duman Ö, Haspolat Ş. Rufinamidin Dirençli Epilepsi Tedavisindeki Etkinliğinin Araştırılması: Tek Merkez Deneyimi. Izmir Katip Celebi University Faculty of Medicine. 2021. doi:10.52818/cjmrtu.2021.1
BibTeX
@article{Saraolu2021,
author = {Saraçoğlu, Mehmet and Bozkurt, Öznur and Duman, Özgür and Haspolat, Şenay},
title = {Rufinamidin Dirençli Epilepsi Tedavisindeki Etkinliğinin Araştırılması: Tek Merkez Deneyimi},
journal = {Izmir Katip Celebi University Faculty of Medicine},
year = {2021},
doi = {10.52818/cjmrtu.2021.1}
}
EUVIMED